wilson htm have come out with a report on acrux saying that...

  1. 461 Posts.
    wilson htm have come out with a report on acrux saying that evamist has been the second best launch of a transdermal product in america.currently new prescription rate of 750 per week.they have put a twelve months target of $2.27.this looks good for the company to sell evamist and other products around the world
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.8¢
Change
-0.002(10.0%)
Mkt cap ! $7.366M
Open High Low Value Volume
1.8¢ 1.8¢ 1.8¢ $8.471K 470.6K

Buyers (Bids)

No. Vol. Price($)
1 50000 1.8¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 370600 1
View Market Depth
Last trade - 13.32pm 25/07/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.